BBIO FY 2021 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+745.1% YoY

Gross Profit

$67M95.5% margin

Operating Income

-$577M-827.1% margin

Net Income

-$563M-806.9% margin

EPS (Diluted)

$-3.90

Cash Flow

Operating Cash Flow

-$498M

Free Cash Flow

-$546M

Stock-Based Comp.

$100M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$1.9B

Stockholders' Equity

-$870M

Cash & Equivalents

$394M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$8M	+745.1%
Gross Profit	$67M	$8M	+707.4%
Operating Income	-$577M	-$474M	-21.5%
Net Income	-$563M	-$449M	-25.4%